--- title: "Rumors of Eli Lilly's acquisition stir the market, French biotech company Abivax's stock price surges in response" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/269237470.md" description: "French biotechnology company Abivax's stock price surged due to market speculation that Eli Lilly might acquire it. Abivax's core product is used to treat ulcerative colitis. The stock price rose more than 10% on the Paris stock market, reaching a market capitalization of approximately 8 billion euros. It rose over 9% in pre-market trading in the U.S. Analysts stated that the stock price volatility stemmed from acquisition rumors. Eli Lilly has not commented on this. Previously, Abivax's stock price also rose due to acquisition rumors" datetime: "2025-12-10T13:35:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/269237470.md) - [en](https://longbridge.com/en/news/269237470.md) - [zh-HK](https://longbridge.com/zh-HK/news/269237470.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/269237470.md) | [English](https://longbridge.com/en/news/269237470.md) # Rumors of Eli Lilly's acquisition stir the market, French biotech company Abivax's stock price surges in response According to the Zhitong Finance APP, French biotechnology company Abivax (ABVX.US) rose on Wednesday in both the Paris stock market and pre-market trading in the U.S. This price movement is reportedly due to market speculation regarding a potential acquisition offer from weight-loss drug giant Eli Lilly (LLY.US). As a clinical-stage biotechnology company, Abivax's core product under research, obefazimod, is primarily used to treat inflammatory diseases such as ulcerative colitis. As of the time of writing, the company's stock price in the Paris stock market has increased by over 10%, bringing its market capitalization to approximately €8 billion (equivalent to $9.3 billion), a significant leap from its valuation of €500 million at the beginning of this year. In pre-market trading in the U.S., the stock rose by over 9%. "The core driving factor behind this stock price fluctuation is market speculation about a potential acquisition deal," said Stifel analyst Damien Choplain. Eli Lilly responded by stating, "We do not comment on business development activities." In fact, this Paris-based company has been involved in acquisition rumors before. Financial intelligence agency Betaville previously released "unverified" market speculation about Abivax potentially being acquired in September and November, both of which drove up its American Depositary Receipt (ADR) prices. Looking back to July of this year, Abivax announced significant positive news: its once-daily oral obefazimod achieved primary endpoints in two Phase III clinical trials for treating ulcerative colitis, leading to a surge in the company's stock price ### 相關股票 - [Abivax SA (ABVX.US)](https://longbridge.com/zh-HK/quote/ABVX.US.md) - [Eli Lilly (LLY.US)](https://longbridge.com/zh-HK/quote/LLY.US.md) ## 相關資訊與研究 - [Eli Lilly: Foundayo will be available with prescriptions accepted immediately and shipping from April 6](https://longbridge.com/zh-HK/news/281395595.md) - [Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | LLY Stock News](https://longbridge.com/zh-HK/news/281171668.md) - [Eli Lilly pushes for NHS drug price increases in return for its UK investment, FT reports](https://longbridge.com/zh-HK/news/280952509.md) - [](https://longbridge.com/zh-HK/news/281203519.md) - [InSilico Medicine's Loss Widens in 2025; Enters Licensing Agreement With Eli Lilly](https://longbridge.com/zh-HK/news/280951810.md)